Business Context and Reporting Period
This Form 8-K is a current report filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on September 27, 2020. The filing discloses the appointment of a new corporate officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the appointment of Ted Randolph as Vice President, Operations. Mr. Randolph, a former employee who served the company from 2007 to April 2020, was re-hired effective September 14, 2020, with his title and salary made retroactive to that date.
Management Commentary and Compensation Terms
- Role: Vice President, Operations (Section 16 Officer).
- Base Salary: $275,000 annually.
- Performance Bonus: Eligible for annual bonuses up to 30% of base salary, subject to Board-established goals.
- Employment Status: At-will employment.
- Severance: If terminated without cause, Mr. Randolph is entitled to six months' advance notice or cash severance equivalent to six months of salary. No severance is provided if terminated for cause.
- Background: Mr. Randolph holds an M.S. in Engineering from Stanford University and a B.S. in Architecture from MIT. His prior experience includes leadership roles at Boston Scientific, Cygnus, and Abbott Laboratories.
Investor Verification Checklist
- Verify the retroactive effective date of September 14, 2020, for salary and title purposes.
- Review the attached Exhibit 10.1 (Employment Offer Letter) for specific performance metrics tied to the bonus structure.
- Confirm the absence of any family relationships between Mr. Randolph and existing directors or officers.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.